Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
To me the most important question was how many improved over the base line. Even the callers did not ask. Did I miss the data on that?
AVXL Due Diligence for new eyes and reference material for old eyes - 8 Sources:
AVXL news:
Webcast and Conference Call Monday December 5, 2022
https://finance.yahoo.com/news/anavex-life-sciences-announce-management-213000909.html
Update Compendium,
Projected Blarcamesine Revenues & Market Cap. Compiled by Mayo:
https://www.sotcanalytics.com/update-compendium
Jun 2022 Commentary on Anavex's First Educational Video:
https://www.anavex.com/vnrjune2022
NEWS: Anavex Announces First Entire Clinical Alzheimer’s Gene Pathway Data of ANAVEX®2-73
https://www.anavex.com/post/anavex-announces-first-entire-clinical-alzheimer-s-gene-pathway-data-of-anavex-2-73-at-aaic-2022
Corporate Slides (DD source).
Anavex programs, trials, graphs, and useful data:
https://www.anavex.com/_files/ugd/79bcf7_3cc5b85e0f1d49bb84e60f933ecbbea8.pdf
Piotrpeterblog.com is an independent analysis blog on Alzheimer and CNS Drugs.
https://piotrpeterblog.com/
An extensive list of various topics with links, compiled DD, and recent posts. Compiled by XenaLives
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=166917727
Report by Dr. Randi Hagerman, a recognized leader WW for CNS conditions and treatments. by tradeherpete.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=168422630
DD for new eyes: AVXL has a deep pipeline for various CNS conditions; and a portfolio of 4 drugs.
A2-73 Blarcamesine for:
Alzheimer's Disease.
Parkinson's Disease.
Rett Syndrome.
Infantile Spasms.
Fragile X.
Angelman's Syndrome.
Undisclosed Rare disease.
A3-71:
Frontotemporal Dementia (FTD).
Neurodegenterative Disease.
A1-41:
Depression.
Stroke.
Neurodegenterative Disease.
A-1066
Visceral Pain
Acute & Neuropathic Pain.
Source link:
https://www.anavex.com/_files/ugd/79bcf7_3cc5b85e0f1d49bb84e60f933ecbbea8.pdf
We have a damn two day weekend coming up before we get to Monday morning when the markets opens again ;>)
A new phase is coming upon Anavex as successful trials will lead to commercialization from sales world wide in the near future.
It's funny how when you suddenly have successful late phase drug trial results, on a stock you are overweight on, that your world becomes full of nice potential possibilities.
GL longs on hanging onto your stock for the full rewards. I say this because Institutional ownership percentage will swell from here, and it will be at the expense of retail investors as that percentage of private ownership will shrink some. Take care with trades to not be left behind unless you taking the cash rewards, I've seen it happen too many times to family and friends and I'm sure you have too, including myself. Some will sell with the intension to buy back more shares when the SP drops, only to watch it go over the horizon.
GLTY Longs and Traders, it's about to become more interesting.
Good luck, and may the best be with all my friends I have found here.
I hope we meet up someday at the annual Meeting.
RedShoulder
From MayoMobile on ST:
MayoMobile
Bullish
12:06 PM
$AVXL
Today is the day.
Starting at 2:30pm EST I will be updating the donor chat in real-time with anything of consequence. 2:30pm through Anavex’s presentation is a special session on emerging therapies and MOAs.
While reading the chat in real-time you may need to refresh your browser every so often.
I’ll see you all at the Zoom meeting later.
(If you haven’t reached out to me for a link at this point you’re too late. Check your spam folder, good luck)
AVXL After-Hours Quotes
Consolidated Last Sale $8.95 +0.01 (+0.11%)
After-Hours Volume 133,445
After-Hours High $8.99 (07:57:38 PM)
After-Hours Low $8.7 (05:05:24 PM)
Missling sounded like he is not expecting to have to run another Alzheimer’s trial.
"Wait for Dec 1st" I like it, gives room for the stock to run up for 4 days.
Press release AVXL: "Earnings announcement* for AVXL: Nov 23, 2022"
https://www.nasdaq.com/market-activity/stocks/avxl/earnings
Based on what, certainly not the Ph-2 results which was historic in that some did not decline and some improved, never has any AD drug accomplished that. Plus the MMSE was raised for the Ph-2b/3 making the bar lower.
ANAVEX®3-71 represents Anavex’s 2nd novel clinical sigma-1 and muscarinic receptor program parallel to ANAVEX®2-73 (blarcamesine). Anavex is developing ANAVEX®3-71 initially for the treatment of Frontotemporal Dementia (FTD), for which ANAVEX®3-71 was previously granted orphan drug designation by the FDA. ANAVEX®3-71
ANAVEX®3-71 recently completed a placebo-controlled Phase 1 clinical trial (ANAVEX®3-71-001). The study successfully reached primary and secondary safety endpoints.5
News Link:
https://finance.yahoo.com/news/anavex-announces-long-lasting-effect-110000200.html
AVXL pipeline for various CNS disease and portfolio of drugs to treat them,
A2-73 Blarcamesine for:
Alzheimer's Disease.
Parkinson's Disease.
Rett Syndrome.
Infantile Spasms.
Fragile X.
Angelman's Syndrome.
Undisclosed Rare disease.
A3-71:
Frontotemporal Dementia (FTD).
Neurodegenterative Disease.
A1-41:
Depression.
Stroke.
Neurodegenterative Disease.
A-1066
Visceral Pain
Acute & Neuropathic Pain.
Source link:
https://www.anavex.com/_files/ugd/79bcf7_3cc5b85e0f1d49bb84e60f933ecbbea8.pdf
Fragile X syndrome (FXS): ANAVEX Announces U.S. FDA Orphan Drug Designation to ANAVEX®2-73 (blarcamesine) for the Treatment of Fragile X Syndrome, Nov 7, 2022
U.S. Food and Drug Administration’s (FDA) has granted Orphan Drug Designation (ODD) to ANAVEX®2-73 (blarcamesine) for the treatment of Fragile X syndrome.
Fragile X syndrome (FXS) is the most common form of inherited intellectual disability and the most frequent single gene cause of autism spectrum disorder with an estimated population of approximately 62,500 in the US and 1,088,500 worldwide.1 At present, there is no approved treatment for Fragile X syndrome.
“The Orphan Drug Designation highlights the potential to expand the therapeutic profile of ANAVEX®2-73 into the largest portion of autism spectrum disorder, Fragile X syndrome,” said Christopher U Missling, PhD, President and Chief Executive Officer of Anavex.
Fragile X Syndrome is the most common form of inherited intellectual disability and the most frequent single gene cause of autism, affecting approximately 1 in 4,000 males and 1 in 6,000 females.
https://finance.yahoo.com/news/anavex-announces-u-fda-orphan-120000960.html
AVXL Due Diligence
AVXL Alzheimer Ph-2b/3 release at CTAD:
https://www.ctad-alzheimer.com/
Update Compendium,
Projected Blarcamesine Revenues & Market Cap. Compiled by Mayo:
https://www.sotcanalytics.com/update-compendium
Jun 2022 Commentary on Anavex's First Educational Video.s:
https://www.anavex.com/vnrjune2022
Anavex Announces First Entire Clinical Alzheimer’s Gene Pathway Data of ANAVEX®2-73
https://www.anavex.com/post/anavex-announces-first-entire-clinical-alzheimer-s-gene-pathway-data-of-anavex-2-73-at-aaic-2022
June Corporate Slides.
Anavex programs, trials, graphs, and useful data:
https://www.anavex.com/_files/ugd/850d88_6d847f744209465f82a4ad655bb25941.pdf
Piotrpeterblog.com is an independent analysis blog on Alzheimer and CNS Drugs.
https://piotrpeterblog.com/
An extensive list of a wide range of various topics with links, compiled DD, and recent posts. Compiled by XenaLives
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=166917727
A report given by Dr. Randi Hagerman, a recognized leader WW for CNS conditions and treatments. Compiled by tradeherpete.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=168422630
Anavex Company, an Overview; compiled by Mayo Mobile:
https://drive.google.com/file/d/15i9suShnAjC_Vq5gEl-ocp3ebsWKr0fd/view
I know that, and this is in the text:
"The short sale volume percent (not short interest)"
BTW short interest is: 10/31/2022 10,105,713
https://www.nasdaq.com/market-activity/stocks/avxl/short-interest
The short sale volume percent (not short interest) for stock ticker AVXL is 68% on Nov 18, 2022. The short sale volume is 249,407. The total volume is 368,412. The short sale volume percent is up 5% compare to Nov 17, 2022.
http://shortvolumes.com/?t=AVXL
Mayo thanks for another in depth analysis.
Quote: " Blarcamesine REGULATES functions. It doesn’t only lower or raise faulty genes/processes, it brings them back to homeostasis regardless of whether the drug needs to boost or reduce processes in particular patients. In this case, calcium regulation may very well be the ultimate upstream lynchpin for most Alzheimer's patients. Without proper nutrient funneling the mitochondria fails to produce ATP. Without enough ATP the 26S proteosome (below) fails to clear proteins, and with an abundance of faulty proteins, the UPR goes into overdrive causing mass cell death via apoptosis."
Quote: "When we look at our active arm in our study, those genes which are down regulated in pathology, they were suddenly up regulated so making them more similar to healthy volunteer level expression. (and)
That happened to 70% of genes which are known to have pathological implications in Alzheimer’s and in Parkinson’s. You see on (this ->) these little circles that exactly the expression of the genes involved in this change of course of the pathology."
Many thanks investor for the transcript.
AVXL Due Diligence for new eyes and reference material:
Alzheimer Ph-2b/3 Top Line Data at CTAD:
https://www.ctad-alzheimer.com/
Update Compendium,
Projected Blarcamesine Revenues & Market Cap. By Mayo:
https://www.sotcanalytics.com/update-compendium
Jun 2022 Commentary on Anavex's First Educational Video.
https://www.anavex.com/vnrjune2022
Anavex Announces First Entire Clinical Alzheimer’s Gene Pathway Data of ANAVEX®2-73
https://www.anavex.com/post/anavex-announces-first-entire-clinical-alzheimer-s-gene-pathway-data-of-anavex-2-73-at-aaic-2022
June Corporate Slides.
Anavex programs, trials, graphs, useful data:
https://www.anavex.com/_files/ugd/850d88_6d847f744209465f82a4ad655bb25941.pdf
Piotrpeterblog.com an independent analysis blog: Alzheimer and CNS Drugs.
https://piotrpeterblog.com/
An extensive list of a wide range of topics, compiled DD, and recent posts. Compiled by XenaLives
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=166917727
Report by Dr. Randi Hagerman, a recognized leader WW for CNS conditions and treatments. By tradeherpete.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=168422630
Anavex Company, an Overview; by Mayo Mobile:
https://drive.google.com/file/d/15i9suShnAjC_Vq5gEl-ocp3ebsWKr0fd/view
$13,50 resistance has been busted, trading higher.
Short report yesterday for 10/31/2022
10,105,713 shares short.
Avg daily vol: 985,598
BEST PART: 10.253382 days to cover.
Where will the MM come up with shares to sell so the shorts can cover? Especially when the Institute Funds and retail is in there buying all the shares the MM can scrape up, leaving scraps for the shorts in a Hard Squeeze.
Thanks Xena for the information and advice on NAC and Glycine.
I do take it along with melatonin before going to bed, I have read it can make you sleepy and I'm good with that.
Per you advice I might break the 1,200 mg dosage down to 600 mg twice a day. On many days I eat only one meal; so it would be taken then and again before bed.
powerwalker, GL on your stress test on the heart.
I have several heart problems that are not lethal in most cases. Atrial flutter, PVCs, and Tachycardia.
My PVCs were a mystery to me that showed up playing tennis; it was a stress test that found the problem.
I did have a 'Watchman' installed into my heart to help prevent strokes. The Watchman is a cover over a useless pocket in the heart that can have blood pool there, then a clot is formed and let loose for a stroke. The cover is quickly overgrown with heart muscle making it safe.I cannot tell or fell that the procedure was done.
I rarely have any of these any more, I like to think that supplements helped.
I hope you have good results on your stress test.
Xena, I have done a lot of research on anti-aging and found that the combo of NAC plus Glycine to be by far the most effective treatment per clinical trial. I plan on taking it until I croak. I hope to live long enough to see a Musk Mars colony which is my interest since my early days with the Apollo Lunar Landing program mapping project.
The FDA has said it is considering making it a prescribed medicine and not over the counter supplement, they are getting a lot of blow back on that proposal. If they do I'll just get it from Canada. Asked why, the FDA said because of the health benefits (paraphrasing).
I have been taking NAC with Glycine (GlyNAC) for about 9 months after reading the antiaging benefits shown in a trial completed by Baylor University. They applied for and received a patent on the combo.
This is not off topic because the trials have shown the combo improves memory and cognition. IMO Alzheimer patients would benefit.
To get the benefits you must take Glycine with the NAC, which does not cost much.
Together they make Glutathione in the body. You can buy Glutathione but it is not absorbed by the body to any significant degree.
Quote: A randomized, double blind human clinical trial conducted by researchers at Baylor College of Medicine reveals that supplementation with GlyNAC – a combination of glycine and N-acetylcysteine – improves many age-associated defects in older humans and powerfully promotes healthy aging. This is relevant because until now, there have been no solutions toward improving many of these age-related declines in people.
Published in the Journal of Gerontology: Medical Sciences, the study shows that older humans taking GlyNAC for 16-weeks improved many characteristic defects of aging. This includes oxidative stress, glutathione deficiency and multiple aging hallmarks affecting mitochondrial dysfunction, mitophagy, inflammation, insulin resistance, endothelial dysfunction, genomic damage, stem cell fatigue and cellular senescence. These were associated with improvements in muscle strength, gait speed, exercise capacity, waist circumference and blood pressure.
“This is the first randomized clinical trial of GlyNAC supplementation in older humans, and it found that a wide variety of age-associated abnormalities improved in older adults supplemented with GlyNAC, while no improvements were seen in those receiving placebo,” said corresponding author Dr. Rajagopal Sekhar, professor of medicine - endocrinology, diabetes and metabolism at Baylor.
The improvements in oxidative stress, glutathione levels and mitochondrial function in the muscle tissue of older humans taking GlyNAC were similar to the improvements in organs such as the heart, liver and kidneys of aged mice supplemented with GlyNAC as reported in the researchers’ recent publication. Taken together, the results of these studies show that GlyNAC supplementation can improve these defects in many different organs of the body. “GlyNAC supplementation in aging mice increased their length of life mice by 24%,” said Sekhar. “Gait speed is reported to be associated with survival in older humans. Our randomized clinical trial found a significant improvement in gait speed in older humans supplemented with GlyNAC. This raises the interesting question of whether GlyNAC supplementation could have implications for survival in people”.
https://www.bcm.edu/news/glynac-supplementation-reverses-aging-hallmarks-in-aging-humans
Another quote:
When giving the older adults GlyNAC:
Glutathione increased by 164% at week 16, comparable to young levels.
Measures of oxidative stress dropped by 74% at week 16, again comparable to young levels.
Gait speed and lower extremity muscle strength improved.
Mitochondrial function improved, according to some (but not all) metrics up to young levels.
A drop in inflammatory markers.
Improvements in insulin resistance and fasting insulin concentrations. No change in fasting glucose concentrations or glucose tolerance tests.
Lower measures of genomic damage.
Increased expression of the mitochondria-supporting gene PINK1.
Indications of improved stem cell function and lowered senescence.
Decreased waist circumference (not body weight and BMI, although there was a non-significant trend in lowering these), and lower systolic (but not diastolic) blood pressure.
No adverse events were reported.
https://medium.com/predict/glynac-as-anti-aging-supplement-a-human-trial-42e9f9c6ae86
If there results of the Alzheimer TLD are what we think, which will be much better than the current SOC or any current drugs in trials, it will be interesting to watch the SP of Biogen which popped over 11 Billion with a drug that showed the 27% reduction in the decline rate; and SAVA which is downstream, redundant, and will be years behind AVXL which will capture the SOC and will be the strong hold there.
Surly some of the sold BIIB and SAVA funds will make there way to AVXL buys if the data looks to become the new SOC once approved.
No and hell no:
"Missling should partner with Biogen!"
Finally turned Green.
$11.80 $0.07 (0.60%)
Vol - 253.5K Heavy Day
I was hoping Missling would not PR anything until the AD TLD was first PRed in which it would have many more eyes, and many more shareholders to build on the AD move up.
Talon, that was only a 5 share trade.
Vol- 45K so far.
Almost all trades were at the closing SP of $11.73.
https://www.nasdaq.com/market-activity/stocks/avxl/after-hours-trades